Intrathecal baclofen, at <1% of the oral dose, is associated with decreased spasticity, stiffness, pain, and discomfort. Baclofen is administered to the spinal cord, using a programmable, subcutaneously-implanted device with a reservoir. The availability of intrathecal baclofen varies among regions and countries. Tizanidine, gabapentin, benzodiazepines, and dantrolene are all oral treatment options for spasticity in MS.

References:
Sammaraiee Y et al. Mult Scler Relat Disord. 2019;27:95-100.